本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
DUBAI, UAE , Jan. 21, 2025 /PRNewswire/ -- Anbio Biotechnology ("Anbio"), a global leader in in-vitro diagnostic technologies, is excited to announce its participation in the 2025 Medlab Middle East exhibition, taking place from 3rd to 6th February at the Dubai World Trade Centre. The event is one of the region's largest and most important medical and laboratory equipment trade shows, bringing together leading manufacturers, distributors, and healthcare professionals from around the globe. Anbio Biotechnology's booth Z1.H50 at 2025 Medlab Middle East Anbio Biotechnology will be showcasing a range of its latest Point-of-Care Testing (POCT) products at Booth Z1.H50. These products include: Dry Chemiluminescence Immunoassay System (Dry CLIA) Immunofluorescence System (FIA) Dry Biochemistry System Colloidal Gold Rapid Tests The company's participation aims to provide healthcare professionals, medical device distributors, and patients in the Middle East, Africa, and Europe with fast, reliable, and cost-effective in-vitro diagnostic solutions that enhance healthcare outcomes. Anbio's Featured Products at Medlab Middle East: Dry Chemiluminescence Immunoassay System The innovative dry chemiluminescence immunoassay system utilizes lyophilized reagents to enhance stability, reduce liquid reagent volume, and improve temperature resistance for room-temperature storage and transport. Compatible with nearly 70 reagents, it covers applications like coagulation, thrombosis, cancer markers, and hormone testing, ensuring reliable results across various clinical settings. Immunofluorescence System Ideal for rapid and precise detection, this immunofluorescence system is a powerful tool for Point-of-Care Testing (POCT). It supports 85 test parameters and is equipped with a built-in battery, allowing up to 8 hours of continuous testing without an external power source. Its versatility makes it suitable for various environments, including laboratories, ambulances, and pharmacies, ensuring reliable diagnostics wherever needed. Dry Biochemistry System The innovative dry biochemistry system ensures simplicity, efficiency, and reliability in various tests, particularly in emergency settings. It utilizes dry reagent strips, with one strip dedicated to each patient, and supports whole blood testing for most assays. The reagents can be stored and transported at room temperature. Offering quick and accurate biochemistry quantification, results are available in as little as 40 seconds, making it the ideal solution for fast-paced environments. Colloidal Gold Rapid Tests These tests provide a quick, easy-to-read, and reliable solution for detecting a variety of infections and conditions, offering fast results for better decision-making in patient care. With a wide range of available reagents, the system covers nearly 100 different test items, making it a cost-effective choice, particularly for large-scale screening. About Medlab Middle East Medlab Middle East is the region's premier event for laboratory and medical professionals, providing access to a vast array of the latest innovations in diagnostics, laboratory management, and medical technology. With thousands of visitors and exhibitors from around the world, it serves as a vital platform for networking, collaboration, and learning about emerging trends in healthcare diagnostics. Anbio Biotechnology's innovative solutions at Medlab Middle East will demonstrate its commitment to advancing the future of diagnostic technology and improving healthcare delivery worldwide. Visit us at Booth Z1.H50 at Medlab Middle East to learn more about our products and how they can transform your healthcare practices.
SANYA, China, Jan. 16, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced significant advances in its biotechnology breeding program and a groundbreaking partnership during the 4th Sanya International Seed Industry Scientist Conference and 2025 International Seed Industry Technology Expo. During his keynote presentation at the conference's Corn Seed Forum, Origin CEO Yan Weibin outlined the Company's strategic vision and latest achievements. "Building long-term strengths and becoming a high-tech seed service company led by biotechnology is Origin's first consideration," stated Mr. Yan. "We are committed to developing into an international seed enterprise with strong scientific research capabilities, team strength, market awareness, variety portfolio, and service capabilities." In a significant development, Origin announced a three-way partnership with China Agricultural University, the world's top-ranked institution in agricultural science, and the Beijing Academy of Agricultural and Forestry Sciences. This partnership establishes a comprehensive research and development initiative focused on corn "smart plant type" improvement and innovative variety development. "By uniting the strengths of these prestigious institutions with Origin Agritech's biotechnology capabilities, we are creating a powerhouse for agricultural innovation," said Yan. "This partnership represents a collaboration that will reshape the future of corn development and smart plant technology." Key Achievements and Capabilities: Establishment of four provincial and ministerial R&D platforms with research bases in Beijing, Hainan, and Henan Development of a large-scale corn genetic platform for efficient functional gene exploration Creation of the world's first corn haploid induction line Hi3 gene editing technology system in collaboration with "Science Exploration Award" winner Professor Tian Feng Accumulation of nearly 300,000 corn germplasm resources Authorization for multiple gene editing traits, including leaf angle, plant height, and rust resistance Obtaining the second-generation BT and GT GMO corn BBL2-2 biosafety certificate in May 2024 Establishing the "Origin Marker Biological Breeding Service Consortium" with China Golden Marker Biotechnology Co., Ltd. and launching four comprehensive biotechnology services: BBL2-2 transgenic applications, molecular marker and variety improvement, gene editing trait improvement, and corn mutant library applications "China's seed industry is at a crucial juncture in biotechnology breeding," added Mr. Yan. "Origin is committed to continuing our substantial R&D investments and providing leading biotechnology services for the seed industry while embracing digital and information technologies to enable multi-dimensional industrial development." Images from the conference are available on the Company's X account: https://x.com/origin_agritech. About Origin Agritech LimitedOrigin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is a leading Chinese agricultural technology company. In crop seed biotechnologies, Origin Agritech's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's website at www.originagritech.com. The Company also maintains an X account for updating investors on Company and industry developments which is https://x.com/origin_agritech. For more information, please contact:Origin Agritech Limited Contact:Kate Lang (Mandarin/English)Director of Investor RelationsPhone: +86 186-1839-3368Email: bing.lang@originseed.com.cn Investor Relations Contact:Matthew Abenante, IRCPresidentStrategic Investor Relations, LLCTel: 347-947-2093Email: matthew@strategic-ir.com
The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors using the comprehensive generative chemistry engine Chemistry42. From initiation to preclinical candidate nomination, the program spanned only 12 months, during which approximately 115 molecules were synthesized and screened. Preclinical studies demonstrate ISM5411 to be gut-restricted and PHD-specific, thus reducing cardiovascular and systematical tumorigenic risks. Two Phase 1 clinical trials of ISM5411 for IBD are currently being conducted in parallel in Australia and China, with the last subject out in both studies. CAMBRIDGE, Mass., Dec. 11, 2024 /PRNewswire/ -- Inflammatory bowel disease (IBD), consisting primarily of ulcerative colitis and Crohn's disease, is a group of debilitating auto-immune disorders, which also increases the risk of colitis-associated cancer. Currently, the standard treatment for IBD mainly consists of anti-inflammatory drugs with limited efficacy and unavoidable side effects, thus millions of IBD patients seek alternative treatment options. Recent studies have correlated the success of mucosal healing with improved prognosis, making mucosal healing an increasingly accepted measure of disease activity in IBD patients. Recently, scientists at Insilico Medicine utilized the comprehensive generative chemistry engine Chemistry42 to discover a novel gut-restricted PHD inhibitor that shows promise for repairing the intestinal mucosal barrier and regulating immune responses in IBD. The study, published in Nature Biotechnology, highlights the role of Chemistry42 and its submodules in supporting drug candidate design and optimization. The research underscores the potential of advanced AI technologies to accelerate the fulfillment of urgent clinical needs. "After we published the first Nature Biotechnology paper in 2019, Insilico got its first big round of $37 million. This milestone enabled us to start our own drug discovery. To date, supported by the Pharma.AI platform, we have nominated 21 preclinical candidates, with 10 molecules receiving IND clearance for clinical trials. The most advanced IPF program has completed a phase IIa safety and preliminary efficacy study, and the discovery and development journal of this program also published in Nature Biotechnology. The PHD program further demonstrates Insilico's ability to consistently advance valuable programs to the clinical stage. In this study, we took less than 12 months to nominate the preclinical candidate, and the paper provides a comprehensive account of our research process and preclinical validation results. During the review process of the paper, we also completed Phase 1 clinical trials in both Australia and China. We look forward to sharing clinical data with the industry in the near future" said Alex Zhavoronkov, the corresponding author of the paper, and Founder and CEO of Insilico Medicine. Insilico initiated the research by focusing on developing therapies that not only reduce gut inflammation but promote epithelial repair. The researchers identified and prioritized HIF-PHD as a therapeutic target for IBD using PandaOmics, a commercially available AI engine for biology research. Then, Insilico employed Chemistry42 and its sub-modules, including generative chemistry, Alchemistry and ADMET analysis modules to design PHD inhibitors with desirable properties. As a starting point, Insilico utilized Chemistry42's structure-based generative chemistry module to initiate fragment growth by pre-establishing a priority fragment and six key pharmacological points based on the reported PHD complex structures. They generated and screened hit compounds with promising activity by enhancing the novelty and synthetic availability filters. Scientists then optimized the properties of the potential candidates using Structure-Activity Relationship (SAR) analysis. They evaluated the generated compounds' potency through Alchemistry to compute binding free-energy estimates for PHD2-ligand complexes and collected the key predicted properties like solubility and permeability via ADMET module to acquire a candidate with a minimized systemic ex2024posure. Ultimately, ISM5411, a potent PHD-specific inhibitor, was obtained. The compound exhibits gut-restrictive pharmacokinetic (PK) profiles and favorable safety in preclinical studies. It demonstrated significant anti-colitis activity at lower doses through restoration of intestinal barrier function and reduction of gut inflammation in multiple experimental colitis models, without the systemic side effects typically associated with PHD inhibition. Based on these studies, ISM5411 was nominated as a preclinical candidate compound for the IBD program after approximately 115 molecules were synthesised and screened within 12 months from project initiation. At the time of this publication, two Phase 1 clinical trials of ISM5411 for the treatment of IBD are being conducted in parallel in Australia and China. The ongoing studies are designed to evaluate the safety, tolerability, pharmacokinetics and food effects of ISM5411 at increasing oral doses in healthy subjects, with the last subject out in both studies. To further evaluate ISM5411 in wider populations, Insilico plans to conduct global multi-center proof-of-concept efficacy studies in patients with ulcerative colitis. In addition to this paper, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001_055, the company's lead drug pipeline with AI-discovered target and AI-designed structure in early 2024. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial, where ISM001_055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage. In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry, medicine development and science research. Powered by Pharma.AI, Insilico has nominated 21 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND clearance for 10 molecules. Reference: 1. Fu, Y., Ding, X., Zhang, M. et al. Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02503-w 2. Ren, F., Aliper, A., Chen, J. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02143-0 About Insilico Medicine Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and generating novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
- VIEH Singapore's Duc Hoa 3 Industrial Park Selected as Premier Location MELBOURNE, Australia, Dec. 6, 2024 /PRNewswire/ -- Core8 Group, an Australian leader in high-tech and biotech innovation, is proud to announce the establishment of the Core8 BioValley Incubator at the Duc Hoa 3 Industrial Park, in Long An Province, Vietnam. This state-of-the-art 12-hectare facility, developed in partnership with Vietnam International Estate Holdings Singapore (VIEH Singapore), will become Vietnam's first comprehensive hub for biotechnology research, talent development, and international partnerships. State-of-the-Art Facilities to Accelerate Biotech InnovationThe Core8 BioValley Incubator will feature a dedicated biotech building to meet the needs of biomedical and agricultural sectors, and include co-sharing spaces and fully equipped laboratories to accelerate innovation, and industry growth. Fostering Collaboration for Global ImpactCore8 BioValley is designed to unite a diverse network of startups, researchers, and established companies. By creating an environment that fosters knowledge sharing and strategic partnerships, the incubator will act as a springboard for groundbreaking solutions addressing global challenges in health and food security. Strengthening Global ConnectionsThe incubator will enhance Vietnam's role in the international biomedical and agricultural markets. By attracting foreign investment and facilitating connections with Taiwan and other global partners, Core8 BioValley will empower local businesses to thrive on an international scale, contributing to Vietnam's economic development and technological leadership. Advancing Vietnam's High-Tech Agenda"The Core8 BioValley Incubator represents our commitment to advancing biotechnology and establishing Vietnam as a hub for high-tech innovation," said Mike Lai, CEO of Core8 Group. "This initiative underscores our dedication to creating opportunities for local talent and fostering global partnerships in the biomedical and agricultural industries." With its advanced facilities, favorable incentives, and strategic location, Core8 BioValley Incubator is set to attract leading biotech enterprises and support Vietnam's aspirations to become a global center of innovation. About Core8 Group Core8 Group, an Australian technology pioneer, has been making significant strides in the high-tech and biotech sectors for over two decades. With a strong presence in Australia and Taiwan, the Core8 Group has established strategic partnerships with industry leaders, positioning itself as a key player in the technology space. www.core8.com.au About Core8 BioValley Incubator To learn more about the Core8 BioValley Incubator and how to connect with us to help bring together startups, researchers, and industry leaders to tackle health and food security challenges, click here: www.core8.com.au/core8biovalley About Duc Hoa 3 Industrial Park The Duc Hoa 3 Industrial Park is a green, clean, and modern 700-hectare manufacturing hub located in Long An Province, Vietnam. Strategically located near major transportation links, the park is designed to foster a dynamic ecosystem that promotes collaboration and sustainable development. Location:Duc Hoa 3 Industrial Park, Tân Hòa, Đức Lập Hạ, Ho Chi Minh City, Long An, Vietnam https://kcnduchoa3.vn https://kcnduchoa3.vn/wp-content/uploads/2022/04/Brochure-KCN-Duc-Hoa-III_Eng_In_Map-Trang-min.pdf
BEIJING, Oct. 21, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, is pleased to announce the establishment of the "Origin Marker Biological Breeding Service Consortium" in partnership with China Golden Marker Biotechnology Co., Ltd. This consortium is designed to license Origin's GMO insect-resistant and herbicide-tolerant (IR/HT) traits to a wider range of industry players and to accelerate the application of Origin's gene editing technology in breeding programs. The signing ceremony for this new initiative took place at the 31st China Seed Industry Conference in Beijing. Signing Ceremony of Origin Marker Biological Breeding Service Consortium The consortium represents a significant step in advancing the commercialization of Origin's cutting-edge GMO and gene editing technologies. Following the Company's receipt of a GMO safety certificate for its transgenic maize, BBL2-2, in May 2024, this consortium will play a key role in promoting the licensing of these GMO traits to seed companies and research institutes., providing a wider opportunity for broader adoption by more industrial players across China's key agricultural regions. In addition, Origin Agritech's breakthrough gene editing technology, including the world's first efficient genetic transformation system for maize induction line Hi3, is central to the consortium's mission. This gene editing system rapidly improves key traits such as drought resistance, plant architecture, and disease resilience in maize, reducing the traditional breeding timeline from 3-4 years to just one. By integrating this technology into Origin's breeding programs and its partners, the consortium seeks to accelerate product development while expanding the royalty opportunities for new, high-performing maize varieties. China Golden Marker Biotechnology Co., Ltd., a leading high-tech biotechnology company specializing in next-generation sequencing (NGS), gene chip detection, and molecular marker technology, plays a pivotal role in this consortium. China Golden Marker has invested 67 million yuan to establish a state-of-the-art molecular marker laboratory capable of processing over 1 million samples and generating over 1 billion SNP data points annually. The consortium is currently advancing three key projects: Commercialization of the BBL2-2 GMO Maize Event: Promoting and seeking partnerships for the commercialization of the insect-resistant and herbicide-tolerant genetically modified BBL2-2 maize. Advancement of Gene Editing for Maize: Promoting the world's first maize-induced gene editing system, which can accurately improve maize leaf angle, drought resistance, and other traits within a year. Innovation in Maize Germplasm Resources: Utilizing the consortium's rich mutant library and molecular marker-assisted breeding techniques to drive innovation in maize germplasm resources. These efforts will support breeding companies and R&D teams in creating more diverse and resilient maize varieties. The consortium has established cooperative relationships with dozens of breeding companies across China and is improving over 100 corn varieties. These varieties are planted in key corn-producing regions, including Donghua North, Huang Huai Hai, Northwest, and Southwest China. Bill Deng, Head of Research at Origin Agritech, commented: "Origin Marker adheres to the concept of 'making breeding easier.' By leveraging modern biotechnology, we are committed to assisting the industry in breeding higher quality, high-yield, and resilient corn varieties with greater accuracy and efficiency. Our consortium will play a crucial role in advancing sustainable agriculture in China." Weibin Yan, Chief Executive Officer of Origin Agritech, commented: "What matters most about this consortium is how it will significantly accelerate the commercialization of our GMO and gene editing technologies by a bigger team and accessibility to more research institutes and seed companies. By combining our groundbreaking innovations with the advanced laboratory capabilities of China Golden Marker, we are streamlining the path from lab to market. This partnership will enable us to bring our high-impact solutions to the agricultural industry faster than ever before." About Origin Agritech Limited Origin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is a leading Chinese agricultural technology company. In crop seed biotechnologies, Origin Agritech's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's website at www.originagritech.com. The Company also maintains a Twitter account for updating investors on Company and industry developments which is https://x.com/origin_agritech. For more information, please contact:Origin Agritech Limited Contact:Kate Lang (Mandarin/English)Director of Investor RelationsPhone: +86 186-1839-3368Email: bing.lang@originseed.com.cn Investor Relations Contact:Matthew Abenante, IRCPresidentStrategic Investor Relations, LLCTel: 347-947-2093Email: matthew@strategic-ir.com
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held in Shanghai from August 27 to 30, 2024, co-hosted by LeadLeo. Based on the research and analysis of the global medical imaging foundation model in recent years, as well as the study and evaluation of related companies in the industry, Frost & Sullivan has awarded Hangzhou Diagens Biotechnology Co.,Ltd. the Global Medical Imaging Foundation Model Innovation Award at the GIL Summit and NIE 2024. Mr. Aroop Zutshi, the Global Managing Partner and Executive Board Member of Frost & Sullivan, and Professor Yu Wang, the Chairman of Chinese Foundation for Hepatitis Prevention and Control and the Former Director General of Chinese Center for Disease Control and Prevention presented this award to Mr. Chengfa Wu, the secretary to the board of Hangzhou Diagens Biotechnology Co.,Ltd. Diagens independently developed the world's leading generalized medical imaging model, and its achievements have been widely recognized Hangzhou Diagens Biotechnology Co.,Ltd. ("Diagens") was founded in 2016, focusing on the core technology innovation of artificial intelligence in medical imaging. The company has independently developed the world's leading generalized medical imaging model and has made significant achievements in the field of artificial intelligence medical imaging. As China's national-level specialized and innovative "Little Giant" enterprise, national technology-based enterprise, and national high-tech enterprise, Diagens has more than 60 core intellectual property rights in China, the United States and Europe, and its scientific and technological achievements have been widely recognized. Among them, the core products of Diagens's artificial intelligence model for medical imaging have obtained 27 certificates from NMPA in China, CE in the EU and FDA in the US, and won the first prize in the Science and Technology Achievement Award of the China Birth Defects Intervention and Relief Foundation, as well as ranked the first in reproductive field in the "Artificial Intelligence Medical Devices" list of the China's Ministry of Industry and Information Technology. Diagens's core technology catches up with overseas, setting a new benchmark for the industry Relying on its deep technical accumulation and excellent innovation ability in the field of medical imaging, Diagens has successfully developed a large model on the medical imaging foundation, which has been applied to karyotype analysis. The system combines the core technology of AI imaging with precision optical equipment, and its world's first third-generation karyotype analysis technology sets up a new benchmark of accuracy and efficiency in the industry. Through this innovative application, the industry's accuracy benchmark has been raised from 50% to 99.45%, and the time for issuing clinical reports has been shortened from nearly 30 days to only 4 days, significantly improving the efficiency. This breakthrough achievement of Diagens has established a new paradigm for global karyotype analysis and has obtained the International First-of-its-kind Equipment Certification. In addition, the technology has been evaluated by the China's national expert group as an international leader in core technology, and the products have been sold to more than 400 China's Grade A tertiary hospitals, providing strong support for clinical diagnosis and treatment. Diagens continues to enhance its technological capabilities for the global medical imaging market The medical imaging foundation large model of Diagens has now been successfully applied to the comprehensive solution of cytogenetic laboratory, which includes fully autonomous, whole process and fully intelligent cytogenetic diagnostic services, such as high-efficiency cultivation, automatic acquisition, automatic preparation, intelligent scanning, intelligent analysis, and online diagnosis. The solution is applicable to many fields such as prenatal diagnosis, assisted reproduction, hematology and oncology, radiation medicine and radiation safety. In the future, Diagens will continue to increase the number of self-developed large models. Targeting the global medical imaging market worth hundreds of billions of dollars, Diagens plans to spend another 3-5 years achieving comprehensive technological leadership in various medical imaging sub-sectors. Through continuous innovation and breakthroughs, Diagens will be committed to providing more efficient and accurate diagnostic tools for patients and healthcare workers, and promoting the sustainable development of the medical imaging field. About Frost & Sullivan's Global Leadership Award The Frost & Sullivan Global Leadership Award recognizes enterprises' outstanding performance and exceptional achievements in areas such as technology innovation, market potential, customer service, branding, and others. The Frost & Sullivan team nominated a group of competitive and excellent enterprises through methods including in-depth interviews, industry analysis, and secondary research. An independent judging panel, made up of third-party investment and financing experts, financial experts, bankers, and renowned listed company entrepreneurs, conducted rigorous evaluations of the nominated enterprises and decided to grant the Global Medical Imaging Foundation Model Innovation Award to Hangzhou Diagens Biotechnology Co.,Ltd.
Biotechnology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
